Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?

References

• Rowen D, Brazier J. Health utility measurement. In: Glied S, Smith P, editors. The Oxford handbook of health economics. Oxford University Press; NY, USA: 2011. p. 788-813
   Google Scholar
• Brazier JR, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford University Press; NY, USA: 2007
   Google Scholar
• Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5(1):1-30
   PubMed Web of Science ®Google Scholar
• Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 2002;12(2):160-78
   PubMedGoogle Scholar
• Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke 2001;32(6):1425-9
   PubMed Web of Science ®Google Scholar
• Stein K, Fry A, Round A, et al. What value health?: a review of health state values used in early technology assessments for NICE. Appl Health Econ Health Policy 2005;4(4):219-28
   PubMedGoogle Scholar
• Tosh JC, Longworth LJ, George E. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. Value Health 2011;14(1):102-9
   PubMed Web of Science ®Google Scholar
• NICE. Guide to the methods of technology appraisal. NICE; London, UK: 2004
   Google Scholar
• NICE. Guide to the methods of technology appraisal. NICE; London, UK: 2008
   Google Scholar
• NICE. Process and methods guides: guide to the methods of technology appraisal 2013. NICE; London, UK: 2013
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. CADTH; Ottawa, Canada: 2006
   Google Scholar
• Lloyd A, Wild D, Gallop K, Cowell W. Reimbursement agency requirements for health related quality-of-life data: a case study. Expert Rev Pharmacoecon Outcomes Res 2009;9(6):527-37
   PubMedGoogle Scholar
• Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to PBAC, Version 4.3.2. PBAC; 2008
   Google Scholar
• Scottish Medicines Consortium. Guidance to manufacturers for completion of new product assessment form (NPAF) (Revised June 2007). SMC; 2007
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35(11):1095-108
   PubMed Web of Science ®Google Scholar
• Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Econ 1996;5(2):141-54
   PubMed Web of Science ®Google Scholar
• Eldabe S, Lloyd A, Verdian L, et al. Eliciting health state utilities from the general public for severe chronic pain. Eur J Health Econ 2010;11(3):323-30
   PubMed Web of Science ®Google Scholar
• Guest JF, Naik N, Sladkevicius E, et al. Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leuk Lymphoma 2012;53(5):928-33
   PubMed Web of Science ®Google Scholar
• Tolley K, Goad C, Yi Y, et al. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ 2013;14(5):749-59
   PubMed Web of Science ®Google Scholar
• Konig HH, Gunther OH, Angermeyer MC, Roick C. Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method. Pharmacoeconomics 2009;27(5):405-19
   PubMed Web of Science ®Google Scholar
• Osborne RH, De Abreu Lourenco R, Dalton A, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health 2007;10(6):451-6
   PubMed Web of Science ®Google Scholar
• Arnesen T, Trommald M. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy 2004;9(1):43-50
   PubMedGoogle Scholar
• Arnesen T, Trommald M. Are QALYs based on time trade-off comparable?--A systematic review of TTO methodologies. Health Econ 2005;14(1):39-53
   PubMed Web of Science ®Google Scholar
• Arnesen TM, Norheim OF. Quantifying quality of life for economic analysis: time out for time tradeoff. Med Humanit 2003;29(2):81-6
   PubMedGoogle Scholar
• Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307(6908):836-40
   PubMed Web of Science ®Google Scholar
• Bozzani FM, Alavi Y, Jofre-Bonet M, Kuper H. A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma. BMC Ophthalmol 2012;12:43
   PubMed Web of Science ®Google Scholar
• Robinson A, Dolan P, Williams A. Valuing health status using VAS and TTO: what lies behind the numbers? Soc Sci Med 1997;45(8):1289-97
   PubMed Web of Science ®Google Scholar
• Attema AE, Edelaar-Peeters Y, Versteegh MM, Stolk EA. Time trade-off: one methodology, different methods. Eur J Health Econ 2013;14(Suppl 1):S53-64
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Feeny DH, et al. The time horizon matters: exploratory results varying the time horizon in time trade-off and standard gamble utility elicitation. In: ISPOR 15th Annual European Congress, Berlin, Germany; 2012
   Google Scholar
• Brazier JE, Rowen D, Mavranezouli I, et al. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technol Assess 2012;16(32):1-114
   Web of Science ®Google Scholar
• Young TA, Rowen D, Norquist J, Brazier JE. Developing preference-based health measures: using Rasch analysis to generate health state values. Qual Life Res 2010;19(6):907-17
   PubMed Web of Science ®Google Scholar
• Brazier J, Dolan P, Karampela K, Towers I. Does the whole equal the sum of the parts? Patient-assigned utility scores for IBS-related health states and profiles. Health Econ 2006;15(6):543-51
   PubMed Web of Science ®Google Scholar
• Feeny DH, Torrance GW. Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples. Med Care 1989;27(3 Suppl):S190-204
   Web of Science ®Google Scholar
• Jansen SJ, Stiggelbout AM, Wakker PP, et al. Patients’ utilities for cancer treatments: a study of the chained procedure for the standard gamble and time tradeoff. Med Decis Making 1998;18(4):391-9
   PubMed Web of Science ®Google Scholar
• Johnston K, Brown J, Gerard K, et al. Valuing temporary and chronic health states associated with breast screening. Soc Sci Med 1998;47(2):213-22
   PubMed Web of Science ®Google Scholar
• Locadia M, Stalmeier PF, Oort FJ, et al. A comparison of 3 valuation methods for temporary health states in patients treated with oral anticoagulants. Med Decis Making 2004;24(6):625-33
   PubMed Web of Science ®Google Scholar
• Matza LS, Secnik K, Rentz AM, et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Qual Life Res 2005;14(3):735-47
   PubMed Web of Science ®Google Scholar
• Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 1998;48(1):25-36
   PubMed Web of Science ®Google Scholar
• Secnik K, Matza LS, Cottrell S, et al. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom. Med Decis Making 2005;25(1):56-70
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16(7):1251-65
   PubMed Web of Science ®Google Scholar
• Wright DR, Wittenberg E, Swan JS, et al. Methods for measuring temporary health States for cost-utility analyses. Pharmacoeconomics 2009;27(9):713-23
   PubMed Web of Science ®Google Scholar
• Torrance GW. Utility measurement in healthcare: the things I never got to. Pharmacoeconomics 2006;24(11):1069-78
   PubMed Web of Science ®Google Scholar
• Ungar WJ. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated? Pharmacoeconomics 2011;29(8):641-52
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011;12(3):219-30
   PubMed Web of Science ®Google Scholar
• Osborne RH, Dalton A, Hertel J, et al. Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study. Health Qual Life Outcomes 2012;10:35
   PubMed Web of Science ®Google Scholar
• Polster M, Zanutto E, McDonald S, et al. A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes. J Med Econ 2010;13(4):655-61
   PubMedGoogle Scholar
• Chancellor J, Aballea S, Lawrence A, et al. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics 2008;26(3):217-34
   PubMed Web of Science ®Google Scholar
• Huang ES, Shook M, Jin L, et al. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care 2006;29(2):259-64
   PubMed Web of Science ®Google Scholar
• Matza LS, Cong Z, Chung K, et al. Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Prefer Adherence 2013;7:855-65
   PubMed Web of Science ®Google Scholar
• Teuffel O, Cheng S, Ethier MC, et al. Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients. Support Care Cancer 2012;20(11):2755-64
   PubMed Web of Science ®Google Scholar
• Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274(23):1839-45
   PubMed Web of Science ®Google Scholar
• Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105
   PubMed Web of Science ®Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71(1):155-65
   PubMed Web of Science ®Google Scholar
• Shah VA, Gupta SK, Shah KV, et al. TTO utility scores measure quality of life in patients with visual morbidity due to diabetic retinopathy or ARMD. Ophthalmic Epidemiol 2004;11(1):43-51
   PubMed Web of Science ®Google Scholar
• Browne C, Brazier J, Carlton J, et al. Estimating quality-adjusted life years from patient-reported visual functioning. Eye (Lond) 2012;26(10):1295-301
   PubMed Web of Science ®Google Scholar
• Kowalski JW, Rentz AM, Walt JG, et al. Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation. Qual Life Res 2012;21(2):323-34
   PubMed Web of Science ®Google Scholar
• Naik RK, Gries KS, Rentz AM, et al. Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis. Qual Life Res 2013;22(10):2801-8
   PubMed Web of Science ®Google Scholar
• Feeny D, Spritzer K, Hays RD, et al. Agreement about identifying patients who change over time: cautionary results in cataract and heart failure patients. Med Decis Making 2012;32(2):273-86
   PubMed Web of Science ®Google Scholar
• Lee GM, Salomon JA, LeBaron CW, Lieu TA. Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual Life Outcomes 2005;3:17
   PubMedGoogle Scholar
• Matza LS, Chung K, Van Brunt K, et al. Health state utilities for skeletal-related events secondary to bone metastases. Eur J Health Econ 2014;15(1):7-18
   PubMed Web of Science ®Google Scholar
• Bala MV, Wood LL, Zarkin GA, et al. Are health states "timeless"? The case of the standard gamble method. J Clin Epidemiol 1999;52(11):1047-53
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Broadwater G, Davis DM, et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol 2009;113(2):216-20
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95(6):683-90
   PubMed Web of Science ®Google Scholar
• Kuppermann M, Shiboski S, Feeny D, et al. Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis. Med Decis Making 1997;17(1):42-55
   PubMed Web of Science ®Google Scholar
• MacKeigan LD, O’Brien BJ, Oh PI. Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes. Med Decis Making 1999;19(2):113-21
   PubMed Web of Science ®Google Scholar
• Kromm SK, Bethell J, Kraglund F, et al. Characteristics and quality of pediatric cost-utility analyses. Qual Life Res 2012;21(8):1315-25
   PubMed Web of Science ®Google Scholar
• Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:54
   PubMedGoogle Scholar
• Tarride JE, Burke N, Bischof M, et al. A review of health utilities across conditions common in paediatric and adult populations. Health Qual. Life Outcomes 2010;8:12
   PubMed Web of Science ®Google Scholar
• Lee JM, Rhee K, O’Grady M J, et al. Health utilities for children and adults with type 1 diabetes. Med Care 2011;49(10):924-31
   PubMed Web of Science ®Google Scholar
• Sung L, Petrou S, Ungar WJ. Measurement of health utilities in children. In: Ungar WJ, editor. Economic evaluation in child health. Oxford University Press; Oxford: 2010
   Google Scholar
• Ratcliffe J, Couzner L, Flynn T, et al. Valuing Child Health Utility 9D health states with a young adolescent sample: a feasibility study to compare best-worst scaling discrete-choice experiment, standard gamble and time trade-off methods. Appl. Health Econ. Health Policy 2011;9(1):15-27
   PubMedGoogle Scholar
• Stevens K. Valuation of the Child Health Utility 9D Index. Pharmacoeconomics 2012;30(8):729-47
   PubMed Web of Science ®Google Scholar
• Sung L, Young NL, Greenberg ML, et al. Health-related quality of life (HRQL) scores reported from parents and their children with chronic illness differed depending on utility elicitation method. J Clin Epidemiol 2004;57(11):1161-6
   PubMed Web of Science ®Google Scholar
• Wittenberg E. Valuing children’s health: whose quality of life matters? Pharmacoeconomics 2012;30(8):633-5
   PubMed Web of Science ®Google Scholar
• Torrance GW. Designing and conducting cost-utility analyses. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven Publishers; Philadelphia, PA, USA: 1996
   Google Scholar
• Lee GM, Salomon JA, Gay C, Hammitt JK. Preferences for health outcomes associated with Group A Streptococcal disease and vaccination. Health Qual Life Outcomes 2010;8:28
   Google Scholar
• Prosser LA, Hammitt JK, Keren R. Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations. Pharmacoeconomics 2007;25(9):713-26
   PubMed Web of Science ®Google Scholar
• Barr RD, Chalmers D, De Pauw S, et al. Health-related quality of life in survivors of Wilms’ tumor and advanced neuroblastoma: a cross-sectional study. J Clin Oncol 2000;18(18):3280-7
   PubMed Web of Science ®Google Scholar
• Noyes J, Edwards RT. EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review. Value Health 2011;14(8):1117-29
   PubMed Web of Science ®Google Scholar
• Payakachat N, Tilford JM, Brouwer WB, et al. Measuring health and well-being effects in family caregivers of children with craniofacial malformations. Qual Life Res 2011;20(9):1487-95
   PubMed Web of Science ®Google Scholar
• Pogany L, Barr RD, Shaw A, et al. Health status in survivors of cancer in childhood and adolescence. Qual Life Res 2006;15(1):143-57
   PubMed Web of Science ®Google Scholar
• Verrips E, Vogels T, Saigal S, et al. Health-related quality of life for extremely low birth weight adolescents in Canada, Germany, and the Netherlands. Pediatrics 2008;122(3):556-61
   PubMed Web of Science ®Google Scholar
• Feeny D, Furlong W, Barr RD, et al. A comprehensive multiattribute system for classifying the health status of survivors of childhood cancer. J Clin Oncol 1992;10(6):923-8
   PubMed Web of Science ®Google Scholar
• Ravens-Sieberer U, Wille N, Badia X, et al. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Qual Life Res 2010;19(6):887-97
   PubMed Web of Science ®Google Scholar
• Wille N, Badia X, Bonsel G, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res 2010;19(6):875-86
   PubMed Web of Science ®Google Scholar
• Stevens K. Developing a descriptive system for a new preference-based measure of health-related quality of life for children. Qual Life Res 2009;18(8):1105-13
   PubMed Web of Science ®Google Scholar
• Stevens K. Assessing the performance of a new generic measure of health-related quality of life for children and refining it for use in health state valuation. Appl Health Econ Health Policy 2011;9(3):157-69
   PubMedGoogle Scholar
• Ratcliffe J, Stevens K, Flynn T, et al. Whose values in health? An empirical comparison of the application of adolescent and adult values for the CHU-9D and AQOL-6D in the Australian adolescent general population. Value Health 2012;15(5):730-6
   PubMed Web of Science ®Google Scholar
• Apajasalo M, Sintonen H, Holmberg C, et al. Quality of life in early adolescence: a sixteen-dimensional health-related measure (16D). Qual Life Res 1996;5(2):205-11
   PubMed Web of Science ®Google Scholar
• Apajasalo M, Rautonen J, Holmberg C, et al. Quality of life in pre-adolescence: a 17-dimensional health-related measure (17D). Qual Life Res 1996;5(6):532-8
   PubMed Web of Science ®Google Scholar
• van Nooten FE, Koolman X, Brouwer WB. The influence of subjective life expectancy on health state valuations using a 10 year TTO. Health Econ 2009;18(5):549-58
   PubMed Web of Science ®Google Scholar
• Dolan P, Roberts J. To what extent can we explain time trade-off values from other information about respondents? Soc Sci Med 2002;54(6):919-29
   PubMed Web of Science ®Google Scholar
• Ashby J, O’Hanlon M, Buxton MJ. The time trade-off technique: how do the valuations of breast cancer patients compare to those of other groups? Qual Life Res 1994;3(4):257-65
   PubMed Web of Science ®Google Scholar
• Buckingham JK, Birdsall J, Douglas JG. Comparing three versions of the time tradeoff: time for a change? Med Decis Making 1996;16(4):335-47
   PubMed Web of Science ®Google Scholar
• Witney AG, Treharne GJ, Tavakoli M, et al. The relationship of medical, demographic and psychosocial factors to direct and indirect health utility instruments in rheumatoid arthritis. Rheumatology (Oxford) 2006;45(8):975-81
   PubMed Web of Science ®Google Scholar
• Tijhuis GJ, Jansen SJ, Stiggelbout AM, et al. Value of the time trade off method for measuring utilities in patients with rheumatoid arthritis. Ann Rheum Dis 2000;59(11):892-7
   PubMed Web of Science ®Google Scholar
• van Osch SM, Wakker PP, van den Hout WB, Stiggelbout AM. Correcting biases in standard gamble and time tradeoff utilities. Med Decis Making 2004;24(5):511-17
   PubMed Web of Science ®Google Scholar
• Mrus JM, Leonard AC, Yi MS, et al. Health-related quality of life in veterans and nonveterans with HIV/AIDS. J Gen Intern Med 2006;21(Suppl 5):S39-47
   PubMedGoogle Scholar
• Yi MS, Britto MT, Sherman SN, et al. Health values in adolescents with or without inflammatory bowel disease. J Pediatr 2009;154(4):527-34
   PubMed Web of Science ®Google Scholar
• Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006;15(10):1121-32
   PubMed Web of Science ®Google Scholar
• Badia X, Monserrat S, Roset M, Herdman M. Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off. Qual Life Res 1999;8(4):303-10
   PubMed Web of Science ®Google Scholar
• Woloshin S, Schwartz LM, Moncur M, et al. Assessing values for health: numeracy matters. Med Decis Making 2001;21(5):382-90
   PubMed Web of Science ®Google Scholar
• Johnston JA, Matza LS, Boye KS, et al. Impact of caregiver status on health state valuations. In: 34th Annual Meeting of the Society for Medical Decision Making. Phoenix, Arizona; 2012
   Google Scholar
• van der Pol M, Shiell A. Extrinsic goals and time tradeoff. Med Decis Making 2007;27(4):406-13
   PubMed Web of Science ®Google Scholar
• Johnson JA, Luo N, Shaw JW, et al. Valuations of EQ-5D health states: are the United States and United Kingdom different? Med Care 2005;43(3):221-8
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002;11(4):341-53
   PubMed Web of Science ®Google Scholar
• Feeny D. Standardization and regulatory guidelines may inhibit science and reduce the usefulness of analyses based on the application of preference-based measures for policy decisions. Med Decis Making 2013;33(3):316-19
   PubMed Web of Science ®Google Scholar
• Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010;11(2):215-25
   PubMed Web of Science ®Google Scholar
• Young TA, Yang Y, Brazier JE, Tsuchiya A. The use of rasch analysis in reducing a large condition-specific instrument for preference valuation: the case of moving from AQLQ to AQL-5D. Med Decis Making 2011;31(1):195-210
   PubMed Web of Science ®Google Scholar
• Brazier J, Tsuchiya A. Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ 2010;19(2):125-9
   PubMed Web of Science ®Google Scholar
• Shaw JW, Johnson JA, Chen S, et al. Racial/ethnic differences in preferences for the EQ-5D health states: results from the U.S. valuation study. J Clin Epidemiol 2007;60(5):479-90
   PubMed Web of Science ®Google Scholar
• Bejia I, Salem KB, Touzi M, Bergaoui N. Measuring utilities by the time trade-off method in Tunisian rheumatoid arthritis patients. Clin Rheumatol 2006;25(1):38-41
   PubMed Web of Science ®Google Scholar
• Bossema ER, Marijnen CA, Baas-Thijssen MC, et al. Evaluation of the treatment tradeoff method in rectal cancer patients: is surgery preference related to outcome utilities? Med Decis Making 2008;28(6):888-98
   PubMed Web of Science ®Google Scholar
• Chen CL, Kuppermann M, Caughey AB, Zane LT. A community-based study of acne-related health preferences in adolescents. Arch Dermatol 2008;144(8):988-94
   PubMedGoogle Scholar
• Khanna D, Ahmed M, Furst DE, et al. Health values of patients with systemic sclerosis. Arthritis Rheum 2007;57(1):86-93
   PubMed Web of Science ®Google Scholar
• Mennini FS, Panatto D, Marcellusi A, et al. Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy. Clin Ther 2011;33(8):1084-95. e1084
   PubMed Web of Science ®Google Scholar
• Saw SM, Gazzard G, Gomezperalta C, et al. Utility assessment among cataract surgery patients. J Cataract Refract Surg 2005;31(4):785-91
   PubMed Web of Science ®Google Scholar
• Schmitt J, Meurer M, Klon M, Frick KD. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 2008;158(2):351-9
   PubMed Web of Science ®Google Scholar